CA3067735A1 - Method of purifying glycosylated protein from host cell galectins and other contaminants - Google Patents

Method of purifying glycosylated protein from host cell galectins and other contaminants Download PDF

Info

Publication number
CA3067735A1
CA3067735A1 CA3067735A CA3067735A CA3067735A1 CA 3067735 A1 CA3067735 A1 CA 3067735A1 CA 3067735 A CA3067735 A CA 3067735A CA 3067735 A CA3067735 A CA 3067735A CA 3067735 A1 CA3067735 A1 CA 3067735A1
Authority
CA
Canada
Prior art keywords
protein
galectin
buffer
matrix
poi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3067735A
Other languages
English (en)
French (fr)
Inventor
Lisa A. Connell-Crowley
Megan J. McClure
Ronald O. Gillespie
Original Assignee
Just Evotec Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Just Evotec Biologics Inc filed Critical Just Evotec Biologics Inc
Publication of CA3067735A1 publication Critical patent/CA3067735A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3067735A 2017-08-17 2018-08-17 Method of purifying glycosylated protein from host cell galectins and other contaminants Pending CA3067735A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762546558P 2017-08-17 2017-08-17
US62/546,558 2017-08-17
PCT/US2018/046919 WO2019036626A1 (en) 2017-08-17 2018-08-17 PROCESS FOR PURIFYING GLYCOSYLATED PROTEIN FROM GALECTINES AND OTHER HOST CELL CONTAMINANTS

Publications (1)

Publication Number Publication Date
CA3067735A1 true CA3067735A1 (en) 2019-02-21

Family

ID=63684424

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3067735A Pending CA3067735A1 (en) 2017-08-17 2018-08-17 Method of purifying glycosylated protein from host cell galectins and other contaminants

Country Status (10)

Country Link
US (1) US11358983B2 (https=)
EP (1) EP3668985B1 (https=)
JP (1) JP7097433B2 (https=)
KR (1) KR102578087B1 (https=)
CN (1) CN111344410B (https=)
CA (1) CA3067735A1 (https=)
DK (1) DK3668985T3 (https=)
ES (1) ES2887046T3 (https=)
MY (1) MY199833A (https=)
WO (1) WO2019036626A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3668985B1 (en) 2017-08-17 2021-06-16 Just-Evotec Biologics, Inc. Method of purifying glycosylated protein from host cell galectins and other contaminants
SG11202110968VA (en) 2019-12-06 2021-10-28 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
AU2021268026A1 (en) 2020-05-08 2023-01-19 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
WO2023192926A2 (en) * 2022-03-30 2023-10-05 Ionis Pharmaceuticals, Inc. Methods for separating certain oligonucleotide compounds
TW202502843A (zh) * 2023-03-17 2025-01-16 日商丸善石油化學股份有限公司 聚合物之製造方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
EP0387319B1 (en) 1988-07-23 1996-03-06 Delta Biotechnology Limited Secretory leader sequences
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
AT403989B (de) 1996-09-16 1998-07-27 Immuno Ag Verfahren zur herstellung eines plasmaprotein-hältigen arzneimittels
DE69738075T2 (de) 1996-11-27 2008-05-21 Genentech, Inc., South San Francisco Affinitätsreinigung von polypeptiden an einer protein a-matrix
US6022952A (en) 1998-04-01 2000-02-08 University Of Alberta Compositions and methods for protein secretion
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
JP4475814B2 (ja) 1998-11-20 2010-06-09 扶桑薬品工業株式会社 タンパク質発現ベクターとその使用
AU4010400A (en) 1999-03-18 2000-10-04 Human Genome Sciences, Inc. 27 human secreted proteins
CN101433715B (zh) 1999-06-08 2013-04-17 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
CA2473144C (en) 2002-02-05 2013-05-28 Genentech, Inc. Protein purification
US7427659B2 (en) 2003-10-24 2008-09-23 Amgen Inc. Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction
ZA200710330B (en) 2005-06-17 2009-12-30 Wyeth Corp Methods of purifying FC region containing proteins
FR2894146B1 (fr) 2005-12-07 2008-06-06 Ifremer Utilisation d'un polysaccharide excrete par l'espece vibrio diabolicus a des fins d'ingenierie des tissus conjonctifs non mineralises
WO2007109163A2 (en) 2006-03-16 2007-09-27 Amgen Inc Wash buffer and method of using
US7998927B2 (en) 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
AU2008206923A1 (en) 2007-01-17 2008-07-24 Merck Serono S.A. Process for the purification of Fc-containing proteins
AR067536A1 (es) 2007-07-17 2009-10-14 Hoffmann La Roche Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea
SG2013061528A (en) * 2008-08-14 2015-03-30 Merck Sharp & Dohme Methods for purifying antibodies using protein a affinity chromatography
NZ592095A (en) 2008-10-20 2013-01-25 Abbott Lab Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography
BRPI0919879A2 (pt) 2008-10-29 2016-02-16 Wyeth Llc métodos para purificação de moléculas de ligação a antígeno de domínio único
WO2011038894A1 (en) 2009-10-01 2011-04-07 F. Hoffmann-La Roche Ag Protein a chromatography
ES2813398T3 (es) * 2009-10-20 2021-03-23 Abbvie Inc Aislamiento y purificación de anticuerpos anti-IL-13 usando cromatografía de afinidad a Proteína A
ES2982297T3 (es) 2009-12-18 2024-10-15 Novartis Ag Método de cromatografía de afinidad
SG191071A1 (en) 2010-12-08 2013-07-31 Amgen Inc Ion exchange chromatography in the presence of an amino acid
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
MX2016016318A (es) * 2014-06-13 2017-06-12 Lupin Atlantis Holdings Sa Proceso para la purificacion de la proteina de fusion.
EP3236772A4 (en) * 2014-12-22 2018-10-17 Alexion Pharmaceuticals, Inc. Methods of purifying recombinant proteins
TW201702380A (zh) * 2015-02-27 2017-01-16 再生元醫藥公司 宿主細胞蛋白質修飾
EP3885368A1 (en) 2015-05-12 2021-09-29 Regeneron Pharmaceuticals, Inc. Multimeric protein purity determination
CN106749660B (zh) * 2016-12-27 2020-02-14 嘉和生物药业有限公司 单克隆抗体下游纯化过程中有效去除宿主蛋白的方法
EP3668985B1 (en) 2017-08-17 2021-06-16 Just-Evotec Biologics, Inc. Method of purifying glycosylated protein from host cell galectins and other contaminants
JP2022520793A (ja) * 2019-02-15 2022-04-01 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド 自動バイオ製造システム、施設、及びプロセス

Also Published As

Publication number Publication date
DK3668985T3 (da) 2021-09-20
CN111344410A (zh) 2020-06-26
KR20200037396A (ko) 2020-04-08
JP2020531411A (ja) 2020-11-05
KR102578087B1 (ko) 2023-09-18
US11358983B2 (en) 2022-06-14
JP7097433B2 (ja) 2022-07-07
US20210163528A1 (en) 2021-06-03
ES2887046T3 (es) 2021-12-21
MY199833A (en) 2023-11-24
CN111344410B (zh) 2023-09-15
EP3668985B1 (en) 2021-06-16
WO2019036626A1 (en) 2019-02-21
EP3668985A1 (en) 2020-06-24

Similar Documents

Publication Publication Date Title
JP6979442B2 (ja) オーバーロード／溶出クロマトグラフィー
US11358983B2 (en) Method of purifying glycosylated protein from host cell galectins and other contaminants
KR101370253B1 (ko) 재조합 항체의 재접힘 방법
JP2024059617A (ja) 精製された組み換えポリペプチドを含む方法及び組成物
JP7397104B2 (ja) アンジオポエチン様４抗体および使用法
US12178874B2 (en) Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
US20230073034A1 (en) Multispecific antibodies, compositions comprising the same, and vectors and uses thereof
TW202112799A (zh) 過載層析管柱之再生方法
AU2010239216B2 (en) Fragmentation resistant IgG1 Fc-conjugates
WO2023108115A1 (en) Ph-selective antibody fc domains
HK40027581B (zh) 从宿主细胞半乳糖凝集素和其他污染物中纯化糖基化蛋白的方法
HK40027581A (en) Method of purifying glycosylated protein from host cell galectins and other contaminants
CN116327963B (zh) 一种眼科制剂及其用途
HK40022824A (en) Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
HK40008360A (en) Aflibercept formulations and uses thereof
HK40008360B (en) Aflibercept formulations and uses thereof
HK40031063B (zh) 具有降低的生物活性的抗体变体和同种型
HK1234415B (en) Angiopoietin-like 4 antibodies and methods of use
CN116327963A (zh) 一种眼科制剂及其用途
HK1170633A (en) Concentrated polypeptide formulations with reduced viscosity

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230526

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240806

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241011

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R107 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRECT APPLICANT REQUEST RECEIVED

Effective date: 20241017

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241101

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241102

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250503

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250504

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250807

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250807

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R13-R109 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRECT APPLICANT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260311

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260311

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260311